DUERLE, BELGIUM–(Marketwire – July 15, 2010) – Remedent, Inc. (OTCBB: REMI), an
international company specializing in research, development, and
manufacturing of oral care and cosmetic dentistry products, reported
results for the final quarter and for the year ended March 31, 2010 (in US
Dollars).

Net sales in the fourth quarter decreased 27% to $2.5 million from $3.4
million in the same year ago quarter. The decrease in sales was due to non
recurring license fees of approx $1 million received from Denmat in the
fourth quarter ended March 31, 2009.

Loss from operations in the fourth quarter was a loss of $111,138 $(0.01)
per share as opposed to a loss of $1,079,063 $(0.05) in the same year-ago
quarter, based upon 20 million weighted average basic shares outstanding.

Net loss for the year ended March 31, 2010 was $2.4 million or $(0.12) per
share, as compared with a loss of $3.0 million or $(0.15) per share for the
year ended March 31, 2009.

Cash and cash equivalents totaled $614,000 at March 31, 2010 as opposed to
$1.8 million at March 31, 2009.

Management Commentary

“Our sales strategy of shifting from our previous wholesale sales (B2B)
model via a distributor to a direct retail model (B2C) is beginning to take
shape. Included in our net loss of $111,000 for the fourth and final
quarter ended March 31, 2010, was a loss of $550,000 directly attributable
to our subsidiary Sylphar. The improved results are attributable to the
inclusion for the first time of our Asian operations into our consolidated
financial statements together with the gain realized from the sale of First
Fit. Sales at all our Spa locations, namely in Beijing, Hong Kong, Taiwan
and in Europe continue to exceed our expectations as sales continue to
climb during the first quarter of the next financial year,” said Guy De
Vresse the CEO of Remedent.

Conference Call Information

Remedent will host a conference call on July 20, 2010 at 11:00 a.m. Eastern
Standard time (8:00 a.m. Pacific time) to discuss these results and its
strategic plans for the future. A question and answer session will follow
management’s presentation. To participate in the call, dial the appropriate
number 5-10 minutes prior to the start time.

Date: Tuesday,  July 20,2010
Time 11:00 a.m. Eastern time (8:00 a.m. Pacific time).
Dial in number: 1-888-677-8749
International: 1-913-312-1482

A simultaneous web cast and replay of the call will be available through
July 31, 2010. The replay pass code is 8101477.

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and
marketing of oral care and cosmetic dentistry products. The company serves
professional dental industry with breakthrough technology for dental
veneers. These products are supported by a line of professional veneer
whitening and teeth sensitivity solutions. Headquartered in Belgium,
Remedent distributes its products to more than 35 countries worldwide. For
more information, go to www.remedent.com.

Statement under the Private Securities Litigation Reform Act of 1995

Statements in this press release that are “forward-looking statements” are
based on current expectations and assumptions that are subject to risks and
uncertainties. Such forward-looking statements involve known and unknown
risks, uncertainties and other unknown factors that could cause Remedent’s
actual operating results to be materially different from any historical
results or from any future results expressed or implied by such
forward-looking statements. In addition to statements that explicitly
describe these risks and uncertainties, readers are urged to consider
statements that contain terms such as “believes,” “belief,” “expects,”
“expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,”
“plan,” “projects,” “project,” to be uncertain and forward-looking. Actual
results could differ materially because of factors such as Remedent’s
ability to achieve the synergies and value creation contemplated by the
proposed transaction. For further information regarding risks and
uncertainties associated with Remedent’s business, please refer to the risk
factors described in Remedent’s filings with the Securities and Exchange
Commission, including, but not limited to, its annual report on Form 10-K
and quarterly reports on Form 10-Q.

                      REMEDENT, INC. AND SUBSIDIARIES
                  CONSOLIDATED STATEMENTS OF OPERATIONS
                                (unaudited)



                           Three months ended            Year ended
                                March 31,                 March 31,
                            2010         2009         2010         2009
                        -----------  -----------  -----------  -----------
Net sales               $ 2,472,815  $ 3,390,355  $ 8,247,940  $14,639,541
Cost of sales               952,189    1,650,315    4,322,680    6,614,723
                        -----------  -----------  -----------  -----------
  Gross profit            1,520,626    1,740,040    3,925,260    8,024,818
                        -----------  -----------  -----------  -----------
Operating Expenses
Research and development     39,850       24,273      271,195      248,652
Sales and marketing         461,078      370,042    1,352,260    2,793,970
General and
 administrative           1,313,812    1,639,656    4,524,324    5,312,192
Depreciation and
 amortization               168,218      173,903      726,499      615,674
                        -----------  -----------  -----------  -----------
TOTAL OPERATING
 EXPENSES                 1,982,958    2,207,874    6,874,278    8,970,488
                        -----------  -----------  -----------  -----------
  OPERATING LOSS           (462,332)    (467,834)  (2,949,018)    (945,670)
                        -----------  -----------  -----------  -----------
NON-OPERATING (EXPENSE)
 INCOME 
Warrants issued pursuant
 to Distribution Agreement       --           --     (168,238)  (4,323,207)
Gain on disposition of OTC       --           --           --    2,830,953
IMDS provision                   --     (300,000)          --     (300,000)
Interest expense/other
 deductions                 (50,596)    (166,972)    (171,364)    (417,147)
Interest income/other
 income                      54,907        1,884      170,244      348,997
Other income                     --           --     (169,358)          --
                        -----------  -----------  -----------  -----------
TOTAL OTHER INCOME
 (EXPENSES)                   4,311     (465,088)    (168,238)  (1,860,404)
                        -----------  -----------  -----------  -----------

LOSS FROM CONTINUING
 OPERATIONS BEFORE
 INCOME TAXES              (458,021)    (932,922)  (3,118,376)  (2,806,074)
Income tax expense          (14,242)     (32,633)     (14,242)     (32,633)
                        -----------  -----------  -----------  -----------

NET LOSS FROM CONTINUING
 OPERATIONS BEFORE
 MINORITY INTEREST         (472,263)    (965,555)  (3,132,618)  (2,838,707)
NET (LOSS) INCOME
 ATTRIBUTABLE TO
 NON-CONTROLLING
 INTERESTS                 (346,683)     114,208     (782,703)     114,208
                        -----------  -----------  -----------  -----------

NET LOSS FROM CONTINUING
 OPERATIONS, ATTRIBUTABLE
 TO REMEDENT INC. COMMON
 STOCKHOLDERS           $  (111,138) $(1,079,763) $(2,349,915) $(2,952,915)
                        ===========  ===========  ===========  ===========

LOSS PER SHARE
Basic and fully diluted $     (0.01) $     (0.06) $     (0.12) $     (0.15)
                        ===========  ===========  ===========  ===========
WEIGHTED AVERAGE
 SHARES OUTSTANDING
Basic and fully
 diluted                 19,995,969   19,995,969   19,995,969   19,559,653
                        ===========  ===========  ===========  ===========

OTHER COMPREHENSIVE
 INCOME (LOSS):
Net loss attributable
 to Remedent, Inc.
 common stockholders    $  (111,138) $(1,079,763) $(2,349,915) $(2,952,915)
Foreign currency
 translation adjustment    (102,949)     (45,371)      (9,464)    (668,245)
                        -----------  -----------  -----------  -----------
Total other comprehensive
 loss                      (214,287)  (1,125,134)  (2,359,379)  (3,621,160)
Less: comprehensive
 (loss) income
 attributable to
 non-controlling
 interest                   (42,623)     (54,700)       7,130      (54,700)
                        -----------  -----------  -----------  -----------
COMPREHENSIVE LOSS
 ATTRIBUTABLE TO
 REMEDENT INC.,
 COMMON STOCKHOLDERS    $  (171,664) $(1,070,434) $(2,366,509) $(3,566,460)
                        ===========  ===========  ===========  ===========




                      REMEDENT, INC. AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS


                                              March 31,2010  March 31,2009
                                              -------------  -------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents                     $     613,466  $   1,807,271
Accounts receivable, net of allowance for
 doubtful accounts of $65,845 at March 31,
 2010 and $33,966 at March 31, 2009                 806,931      3,208,120
Inventories, net                                  2,161,692      1,937,946
Prepaid expense                                     920,487      1,310,900
                                              -------------  -------------
Total current assets                              4,502,576      8,264,237
                                              -------------  -------------
PROPERTY AND EQUIPMENT, NET                       1,735,719      1,024,999
OTHER ASSETS
Long term investments and advances                  750,000        750,000
Patents, net                                        246,992        163,106
Goodwill                                            699,635             --
                                              -------------  -------------
Total assets                                  $   7,934,922  $  10,202,342
                                              =============  =============
LIABILITIES AND STOCKHOLDERS' EQUITY
 (DEFICIT)
CURRENT LIABILITIES:
Current portion, long term debt               $     215,489  $      78,798
Line of Credit                                      674,600        660,200
Accounts payable                                  1,932,684      1,398,420
Accrued liabilities                                 491,536      1,590,360
Due to related parties                              268,484             --
Income taxes payable                                     --         39,339
                                              -------------  -------------
Total current liabilities                         3,582,793      3,767,117
  Long term debt less current portion               425,882        100,542
                                              -------------  -------------
Total liabilities                                 4,008,675      3,867,659
                                              -------------  -------------

EQUITY:
Preferred Stock $0.001 par value (10,000,000
 shares authorized, none issued and
 outstanding)                                           --            --
Common stock, $0.001 par value; (50,000,000
 shares authorized, 19,995,969 shares issued
 and outstanding at March 31, 2010 and
 19,995,969 shares issued and outstanding at
 March 31, 2009)                                     19,996         19,996
Treasury stock, at cost; 723,000 and 723,000
 shares at March 31, 2010 and March 31, 2009
 respectively                                      (831,450)      (831,450)
  Additional paid-in capital                     24,742,201     24,106,055
Accumulated deficit                             (19,565,943)   (17,216,028)
Accumulated other comprehensive income (loss)
 (foreign currency translation adjustment)         (650,059)      (640,595)
Obligation to issue shares                           97,500             --
                                              -------------  -------------
Total Remedent, Inc. stockholders' equity         3,812,245      5,437,978
                                              -------------  -------------
Non-controlling interest                            114,002        896,705
                                              -------------  -------------
Total stockholders' equity                        3,926,247      6,334,683
                                              -------------  -------------
Total liabilities and equity                  $   7,934,922  $  10,202,342
                                              =============  =============

SPRING, TX–(Marketwire – July 15, 2010) –  Dallas-based developer The LaSalle Group, Inc. is breaking ground on its third specialized Alzheimer’s and Memory Care Assisted Living Community in the Houston area, Autumn Leaves of Cypresswood, in Spring, TX. Company leadership, principal investors and other key partners will gather to see the newest addition to the Autumn Leaves family at official ground breaking ceremonies Tuesday, July 20 beginning at 11:00 a.m. Ceremonies will take place at the Cypresswood site located at 6327 Cypresswood Drive in Spring, TX. Local media and Spring area officials are invited to attend as well. 

Research of the Houston area has continued to show a demand for dedicated Alzheimer’s beds that exceeds the current supply. “We will continue to develop in the Houston market,” said Mitchell Warren, President of The LaSalle Group. “Our partners and investors recognize the pent-up need for our dedicated services that cater to this specific population and based on our in-depth market research results, we are committed to continuing our growth pattern in this market.” Autumn Leaves of Cypresswood will be the 15th property developed by LaSalle over the past ten years. Currently, The LaSalle Group has nine Autumn Leaves communities operating successfully in the Dallas/Fort Worth market and three in the greater Chicago area. The first Houston property to open, Autumn Leaves of The Woodlands, is set to accept their first residents in August; construction on the second Houston property, Autumn Leaves of Riverstone, is underway in Missouri City and scheduled to be completed in early Spring 2011. The company plans to continue their current expansion into the Houston market opening new communities in the area over the next three years.

Autumn Leaves of Cypresswood is scheduled to be completed and accepting residents by late Spring 2011. The property will feature 38 units and accommodate approximately 46 residents. For more information on this or other LaSalle Group projects, contact the home office at (214) 239-8400.

Construction and Management
Lake Superior Contracting, LaSalle’s in-house, full-service construction division, will coordinate and manage the design and construction of the new property ensuring the distinctive, research-based structural design attributed to all of LaSalle’s Autumn Leaves communities is in place. Sister firm Constant Care Management Company will manage and oversee all of the day-to-day operations once the community opens.

About The LaSalle Group, Inc. 
Family-owned and operated, The LaSalle Group (with its subsidiaries and affiliates) develops, builds, manages and owns specialized assisted living residences for people with Alzheimer’s and other forms of memory impairment, as well as other specialized real estate properties throughout the United States. For more information about our business, companies and current projects visit http://www.LaSalleGroup.com or call 1-800-452-7255. “Our Family Caring For Your Family”

About Alzheimer’s Disease
Alzheimer’s disease is a fatal and progressive brain disease that affects over 5.3 million Americans. Currently there is no cure and medications do not stop or reverse the disease. As the most common form of dementia, it accounts for more than approximately 60% of dementia cases.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 15, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical manufacturing and biotechnology analytics company, has sold an interest in MedBioWeb, Corp., in exchange for 150 million shares of its common stock, thereby reducing the actual issued and outstanding shares of Healthnostics, Inc., to 155,857,509.

As the Company refocuses its business, it is contemplating the possibility of a sale of its remaining interest in MedBioWeb Corp. MedBioWeb Corp. may more readily achieve its profit goals as an independent company and Healthnostics, through its recent acquisition, may be more able to show a substantial increase in per share earnings due to the near halving of outstanding shares.

The Company will continue to pursue acquisitions that are both compatible and synergistic.

“The Company is witnessing dramatic changes, all of which we believe bode well for our stockholders. We are focusing on profitability and earnings per share, factors that will enhance our ability to thrive and grow,” said Alan Grofe, president.

About Healthnostics
Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: Worldwide Wipes Co., a manufacturer and distributor of medical and other wipes, MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.
For further information please visit Healthnostics www.healthnostics.com, and Worldwide Wipes Co. www.wipesco.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

TUSTIN, CA–(Marketwire – July 15, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has launched a new investor video channel on its corporate website (www.radient-pharma.com) to deliver regularly scheduled, dynamic video content to Wall Street and the investing community. The videos are also available at: http://radient.investorcandy.com/radient/RD#videos.

Investor communications through RPC’s new investor video channel will be delivered on a regular basis and will cover a broad range of topics and information, including personalized messages from RPC’s executive team, breaking company news, and in-depth updates on the Company’s business and product commercialization strategy, execution, timeline and progress. RPC also plans to leverage its online video channel as a medium to communicate to other key audiences beginning in the third quarter of 2010. Targeted audiences include distributors, strategic partners, oncologists, general practice physicians and cancer patients who may have used or are considering using RPC’s Onko-Sure in vitro diagnostic cancer test. 

“Video is becoming increasingly important as a way of reaching investors and business partners with valuable information,” commented RPC’s Chairman and CEO Mr. Douglas MacLellan. “RPC’s new Investor Video Channel is an excellent complement to our just launched corporate website and an excellent channel to communicate business activities that are of material importance our investing community.”

Updates on the availability of new content will be broadly communicated through the issuance of press releases. For additional information on RPC visit the Company’s website located at www.radient-pharma.com or contact RPC Investor Relations at 206.310.5323 or [email protected].

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products, including the company’s Onko-Sure in vitro diagnostic (IVD) cancer test — a simple, non-invasive, patent-pending and regulatory-approved test used for the detection, screening, and monitoring of various types of cancer. Onko-Sure is approved by: the US FDA for the monitoring of colorectal cancer; Health Canada as a lung cancer screen and as a cancer monitoring tool; and as a cancer monitoring or cancer screening test in the European Union, India, Korea, and Taiwan. Visit www.Radient-Pharma.com for additional information.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 15, 2010) –  (PINKSHEETS: SREH) — SREH CEO, Tony Dibiase, announces the official launch of the company’s website, www.SREHoldings.com, “toward overall branding, marketability, transparency and developing a strong corporate identity as a publicly traded holdings company. The site has been designed to provide easy access to information about SREH’s subsidiary companies, Mobile2Earth (www.mobile2earth.com) and Scientific News International (www.scientificnewsroom.com) both with a rich base of intellectual property as well as IP development internally and for clients,” states Dibiase.

www.SREHoldings.com is a clean interface for a user-friendly experience featuring company overviews, news, progress and updates. “The new website exemplifies the dynamism and scope of SREH and its subsidiaries. Serving as a home base, the website provides both existing and prospective clients and shareholders timely, quality information about SREH and its subsidiaries with links to each individual company’s website therein. Mobile2Earth and SNI are not exactly sexy companies, per se,” states Dibiase. “But therein lies a trademarked and 13 year industry tested news service, subscription based social networking, exclusive non-biased content for medical professionals, iPhone and iPad apps as members of the Apple Developer Connection, to start. They both feature highly unique, marketable IP that can lead to sexy growth and corporate expansion. The SREH website helps exhibit all that we do in an easily digestible form, with the individual company sites available for customers, clients and the like with branding in place, accordingly. Both companies feature robust capabilities and the new holdings page simplifies this and strengthens our brand all the while.”

The company has submitted current disclosure and financial documents with OTCMarkets and will announce an update in tier status once reflected on the site.

CUTTING EDGE MEDICAL MEETING NEWS EXCLUSIVELY AT Scientific News International! (www.scientificnewsroom.com) is SREH’s premiere all-in-one platform for medical conference and news information focusing on Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology and Urology. The site is the web’s only online resource for medical professionals with access to the latest, cutting edge data presented at major medical meetings worldwide. Staffed by global medical writers, SNI reports the most current research and therapy findings directly. The site’s profitability is IP and subscription based without bias from any medical or pharmaceutical provider. 

In the beginning, there was…Fishing, Manga, global tide reports and more! Get your iphoneMobile2Earth (www.mobile2earth.com) app now. Choose from the iphone King James Bible, fishing reports worldwide, Japanese e-books and comics and so much more as Mobile2Earth unleashes phase 1 of its iphone app releases for mass consumption. 

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

CAMBRIDGE, MA–(Marketwire – July 15, 2010) –  PharmaPros, a technical consulting and solutions provider specializing in data and workflow management for clinical trials, today announced that Medelis, a single-source provider for oncology drug development services, has selected PharmaPros’ recently launched eClinical OnDemand™ solution, a unique Software as a Service (SaaS) subscription model for data and technology management.

With eClinical OnDemand™, PharmaPros acts as an outsourced technology department providing all of the technology implementation, management, and support for an end-to-end eClinical suite, as a managed service accessible by the study, program, or as a functionally outsourced department. With this solution, small to mid-sized organizations gain the advantage of a seasoned technology team and best-in-class clinical technology suite delivered with the added value of Dataflow Manager, PharmaPros’ first-in-class study management solution. With Dataflow Manager as the solution’s central interface, study teams can collaborate on study management operations using real-time data intelligence, across systems, sources, and vendors.

“We are excited to have been selected by Medelis to provide this solution. PharmaPros has a unique domain expertise at the intersection of data and technology. This enables us to not only deliver the highest quality services, but to enable specialty service providers to focus on their core competencies and deliver innovative solutions,” said PharmaPros CEO, Peg Regan.

PharmaPros will provide additional services to support both EDC and paper based studies using their proprietary methodology: electronic Data Lifecycle Management (eDLM) in conjunction with Dataflow Manager. With the advantage of an integrated study workflow and access to in-stream study progress, Medelis and PharmaPros will work seamlessly throughout the trial to ensure the expected data lifecycle, trial milestones, and data availability are managed to expectation.

“We are pleased to have found this unique solution to extend our own service offerings. eClinical OnDemand™ has enabled us meet client requirements for progressive technology, in-stream study status and integrated data extracts on-demand, providing us a competitive advantage we would not have with other, more traditional outsourced solutions,” said Bob Bosserman, CEO of Medelis Inc.

PharmaPros’ eClinical OnDemand™ is the first solution of its kind in the industry. Providing small to midsize companies a fully integrated eClinical technology suite, supported by mission critical services to ensure data is managed and available on a continuum from start-up to analysis. Integrated data from all sources including sites, labs, and imaging centers are delivered through PharmaPros study management application Dataflow Manager, providing study teams an unparalleled view of study progress.

About PharmaPros Corporation
PharmaPros Corporation is a technical consulting and solutions provider specializing in data and technology for clinical trials. The company’s innovative approach and deep industry expertise, has resulted in the commercialization of a revolutionary solution that is redefining clinical trials management. The company’s premiere solution — Dataflow Manager™ — provides the ability to manage clinical trials using the most accurate and up-to-date information available, enabling trial sponsors and managers to make more rapid, and better-informed decisions during a trial. PharmaPros was formed in 1996, with headquarters in Cambridge, MA.

SOUTH SAN FRANCISCO, CA–(Marketwire – July 15, 2010) –   Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the European Patent Office (EPO) has granted a European patent covering combinations of the Company’s lead drug candidate, voreloxin, with cytarabine. Cytarabine is the standard-of-care treatment for Acute Myeloid Leukemia (AML), and the therapy used in combination with voreloxin in a fully enrolled Phase 2 trial in patients with relapsed and/or refractory AML. Sunesis has also announced plans to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year. European Patent No. 1 729 770 B1, titled “SNS-595 [voreloxin] and Methods of Using the Same,” following completion of the patent validation process, will provide patent coverage for such combination products in 30 member states of the European Patent Convention, including the major European markets, through 2025. Corresponding patent applications are pending in major markets throughout the world including Australia, Canada, Japan and the United States. 

“This patent is an important new addition to our intellectual property estate, as it covers the combination of voreloxin and cytarabine, the contemplated initial market application,” stated Daniel Swisher, Chief Executive Officer of Sunesis. “We are pursuing a sophisticated and deliberate strategy to provide exclusive coverage in the voreloxin patent estate out to 2030. Beyond our granted patents, we have filed patent applications covering formulations, combination uses, dosing, manufacturing processes and composition of matter claims. We look forward to the successful prosecution of these patent applications in multiple territories around the world.”

About Voreloxin

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a fully enrolled single agent Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a fully enrolled Phase 2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. A Phase 2 single agent clinical trial in platinum-resistant ovarian cancer has also completed enrollment. Sunesis plans to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The National Cancer Institute estimated that nearly 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. in 2009. Additionally, it is estimated that prevalence of AML is approximately 25,000 in the U.S. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

This press release contains forward-looking statements, including without limitation statements related to the prosecution of patent applications and Sunesis’ plans to initiate a pivotal Phase 3 clinical trial of voreloxin in the second half of this year. Words such as “evaluate,” “planned,” “will,” “look forward” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis’ current expectations. Forward-looking statements involve risks and uncertainties. Sunesis’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include without limitation, risks related to Sunesis’ need for additional funding to fully finance the planned voreloxin pivotal trial, the risk that Sunesis’ development activities for voreloxin could be halted or significantly delayed for various reasons, the risk that Sunesis’ clinical studies for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends may not be predictive of future data or results, the risk that Sunesis’ nonclinical studies and clinical studies may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis’ clinical trials, risks related to the manufacturing of voreloxin, and the risk that Sunesis’ proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under “Risk Factors” and elsewhere in Sunesis’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

MARKHAM, ONTARIO–(Marketwire – July 15, 2010) – Extendicare Real Estate Investment Trust (“Extendicare REIT” or the “REIT”) (TSX:EXE.UN) today announced that it has declared a cash distribution of C$0.07 per unit of the REIT (the “REIT Units”) for the month of July 2010, which is payable to unitholders of record at the close of business on July 30, 2010, and will be paid on August 16, 2010.

Extendicare Limited Partnership (the “Partnership”) also announced that it has declared a cash distribution of C$0.07 per Class B limited partnership unit (the “Exchangeable LP Units”) for the month of July 2010, which is payable to unitholders of record at the close of business on July 30, 2010, and will be paid on August 16, 2010.

The current annualized distribution rate of the REIT and Partnership is C$0.84 per unit, payable in monthly distributions of C$0.07 per unit. In accordance with the distribution policy of both the REIT and the Partnership, unitholders of record at the close of business on the last business day of each calendar month will be paid a distribution on or about the 15^th day of the following month.

Management estimates that approximately 70% of the 2010 distributions of the REIT and Partnership will be characterized as tax-deferred returns of capital for Canadian residents. To the extent the remaining 30% of distributions of the REIT and Extendicare LP to be made in 2010 are taxed as dividends, those paid to Canadian residents are eligible dividends as per the Income Tax Act (Canada). The REIT is not required to, and does not, calculate its “earnings and profits” pursuant to the United States Internal Revenue Code of 1986, as amended, and therefore no portion of its distributions represent qualified dividend income for U.S. tax purposes.

The REIT has a Distribution Reinvestment Plan, which provides Canadian resident holders of REIT Units and Exchangeable LP Units with the opportunity to increase their respective investments at a 3% discount to the volume weighted average trading price of the REIT Units on the TSX for the five trading days immediately preceding the distribution payment date. A copy of the Plan package is available under the investors section of the REIT’s website.

About Us

Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,700 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 258 senior care centers in North America have capacity for approximately 28,900 residents. Extendicare REIT is a specified investment flow-through trust (SIFT) that has been subject to the SIFT tax since January 1, 2007.

Forward-looking Statements

Information provided by Extendicare REIT from time to time, including this release, contains or may contain forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to the REIT and its subsidiaries, including its business operations, business strategy, and financial condition. Forward-looking statements can be identified because they generally contain the words “expect”, “intend”, “anticipate”, “believe”, “estimate”, “project”, “plan” or “objective” or other similar expressions or the negative thereof. Forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available, and the REIT assumes no obligation to update or revise any forward- looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the REIT to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on the REIT’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare REIT with the securities regulatory authorities, available at www.sedar.com and on the REIT’s website at www.extendicare.com.

PORT ST. LUCIE, FL–(Marketwire – July 15, 2010) –  RightSmile, Inc. (PINKSHEETS: RIGH) (www.RightSmile.com), the leader in Cosmetic Laser Teeth Whitening, continues to add more SmileShoppes across the country, while adding monthly reoccurring revenue at the same time. Furthermore, the Company will be reducing the current amount of shares outstanding by nearly 500 million shares within the coming days.

RIGH has been adding more SmileShoppes from the efforts of the independent rep groups recently signed up. Each SmileShoppe delivers monthly reoccurring revenue to the Company of approximately $500 per month, by just adding 10 new SmileShoppes per month at the end of a year the Company will have added $60,000 a month in additional revenue. The Company also has its first full time, in-house sales person, working from the corporate office in FL, and has been making good headway into the South Florida market.

The Officers of RIGH have decided to exchange their shares of Common stock for Preferred stock to ease investors’ minds that they may be selling their shares into the market. “Management is focused on building strong shareholder value and letting the shareholders know we are in it for the long haul,” stated Gene Caiazzo, President.

This reduction will reduce the Outstanding shares of the company’s Common stock to 550,000,000 from currently over 1 billion.

The Company has been working diligently on compiling and delivering all the information asked for by the audit team and looks forward to posting the audited financials on PinkSheets.

Once the financials are complete the company will hold its Annual Shareholders meeting this August in Fort Lauderdale, FL. As previously announced, all shareholders who attend the meeting can get their teeth whitened for free.

About RightSmile®:

Based in Port St. Lucie, Florida, RightSmile, Inc. engages in the distribution of branded and private label Cosmetic Laser Teeth Whitening products. Through Revodent, RIGH became a manufacturer of teeth whitening products. Revodent supplies numerous manufacturers/manu-packagers with components for teeth whitening solutions; in addition, they also supply final products designed for use in the dental, salon/retail and internet markets.

The Company believes all remarks made in the release to be accurate to the best of its knowledge.

The foregoing press announcement contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Click here to see all recent news from this company

ONTARIO, CA–(Marketwire – July 15, 2010) – Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products is pleased to announce they are in the process of adding an additional prescription drug to their product line. This drug known as Fortex is used for the relief of pain and inflammation of musculoskeletal conditions such as arthritis and muscle soreness.

Fortex will be prescribed by orthopedic surgeons, rheumatologists, general practitioners and pharmacists throughout Canada. Under the terms of the exclusive license agreement, Axxess Pharma will have sole rights to manufacture and market the prescription drug in Canada. The Company anticipates this prescription drug will provide a significant source of residual revenue due to the continued increase of senior citizens and overworked population.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Safe Harbor

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

ALEXANDRIA, VA–(Marketwire – July 14, 2010) –  On Wednesday, July 14, the Obama Administration joined medical professionals and leaders from the health community to announce preventive health care coverage made available under the Affordable Care Act. Under this act, new insurance plans are required to provide preventive care without cost-sharing, which will remove financial barriers for many Americans for preventive services that can help alleviate disease and reduce costs. 

The American Diabetes Association believes that while this is laudatory, relying exclusively on the United States Preventive Services Task Force (USPSTF) “A and B” recommendations, will not lead to adequate screening of patients at risk for diabetes. Blood glucose screening is one of the most essential tools for detecting diabetes and something that should be part of a basic package of benefits and services. 

Under the new rule, asymptomatic adults with sustained high blood pressure will have access to diabetes screening and adults and children will have access to obesity screening and counseling through their clinician at no cost. Ensuring that patients with other risk factors, such as a family history of diabetes or who are obese, also have access to preventive screenings at low or no cost will allow for earlier diagnosis and subsequent prevention of dangerous and costly complications. 

Through implementation of the Affordable Care Act we must ensure that patients at high risk of diabetes are screened for the disease when they see their primary care physician. Nearly 6 million of the 24 million Americans living with diabetes have not been diagnosed. There is an additional 57 million Americans with pre-diabetes, and nearly 93 percent do not know it. If left untreated, diabetes leads to costly and dangerous complications such as blindness, amputation, heart disease, and kidney disease. Relying solely on the USPSTF recommendation, which gives an “I” statement to blood glucose screening for any asymptomatic patient not experiencing high blood pressure, will continue to leave millions of Americans undiagnosed and in danger of facing otherwise avoidable health complications such as blindness, amputation, heart disease, and kidney disease.

We are supportive of the provisions that cover obesity screening and other diabetes-related prevention services. We look forward to working with the Obama Administration and Congress to ensure that people have access to diabetes screenings, as well as to the preventive services that help to manage the disease and prevent complications following diagnosis.

American Diabetes Association guidelines (below) recommend screening for individuals who meet the common risk factors for diabetes. These criteria are consistent with those used in scientific studies of diabetes prevention.

• All adults who are overweight and have additional risk factors:
  • Physical inactivity
  • First degree relative with diabetes
  • Women diagnosed with gestational diabetes or who delivered a baby weighing > 9 lb.
  • Hypertension (high blood pressure) or cholesterol abnormality
  • Other clinical conditions associated with resistance to the effects of insulin
• In the absence of the above criteria, testing should begin at age 45 years
• If results are normal, testing should be repeated at least at 3 year intervals, with consideration of more frequent testing depending on initial results and risk status.

The American Diabetes Association believes that targeted diabetes screening as outlined by the our recommendations and supported by the National Institute of Diabetes and Digestive and Kidney Diseases, and are in line with risk factors recommended by the Centers for Disease Control and Prevention must be considered a covered preventive service. Doing so will meet the dual goals of the Affordable Care Act, that is emphasizing prevention and reining in healthcare costs.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

SAN FRANCISCO, CA–(Marketwire – July 6, 2010) –  New decorative contact lenses called circle lenses are an emerging and potentially dangerous trend among teenagers and young adults. In response to this, the American Academy of Ophthalmology (Academy) would like to alert consumers to the hazards of buying any decorative lenses, including circle lenses, without a prescription. Any type of contact lens is a medical device that requires a prescription, proper fitting by an eye care professional and a commitment to proper care by the consumer.

Inflammation and pain can occur from improperly fitted, over-the-counter lenses and lead to more serious problems including corneal abrasions and blinding infections.

Although over-the-counter sales of nonprescription “plano” cosmetic lenses have been illegal in the United States since 2005, they are still widely available without prescription in retail stores and on the Internet. In 2005, an Academy-backed federal law classified all contact lenses as medical devices and restricted their distribution to licensed eye care professionals.

To protect your eyes, all contact lenses must be fitted by an eye care professional. If you have any pain, burning, redness, tearing or sensitivity to light while wearing any type of contact lenses, see your ophthalmologist, an Eye M.D. For more information about contact lenses, go to www.geteyesmart.org.

Media: Spokespeople are available to comment.

About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons — Eye M.D.s — with more than 29,000 members worldwide. Eye health care is provided by the three “O’s” — opticians, optometrists and ophthalmologists. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases and injuries, and perform eye surgery. To find an Eye M.D. in your area, visit the Academy’s Web site at www.aao.org.

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – July 6, 2010) –  The Cystinosis Research Foundation of Irvine, Calif., announced it has awarded $988,759 in grants to seven specialized research studies in the United States, France, Belgium and Ireland that are focused on finding a cure for cystinosis and improving understanding of the rare, deadly metabolic and genetic disease. Cystinosis afflicts about 500 children and young adults in the U.S. and 2,000 worldwide.

“The $11.8 million in cystinosis research grants awarded to date has resulted in an important milestone. The CRF’s mission to find a better treatment for cystinosis has been realized with the final Phase 3 clinical trial of Delayed-Release Cysteamine currently under way at Emory University and soon to be at several other sites in the U.S. and Europe. Without the concerted effort of CRF, we would not be where we are today. We are very close to unlocking the mysteries of this terrible disease,” said Nancy Stack, CRF Trustee and President.

The CRF is the leading funding source for bench and clinical investigations of cystinosis worldwide.

The foundation’s latest round of funding follows the recent formation of the CRF Cystinosis Gene Therapy Consortium. The consortium’s goal is to advance progress on the most promising current findings, including moving novel therapeutic modalities into human patients as quickly as possible. Work is now under way at The Scripps Research Institute in La Jolla, Calif., to develop the necessary preclinical animal model data and translate these results into an FDA-approved clinical trial.

The CRF is launching the Cure Cystinosis International Registry (CCIR), whose purpose is to consolidate information about cystinosis patients into a single data repository which will help advance research and clinical trials leading to future treatments and cures.

The CRF awards research grants in the spring and fall of each year. The latest round of funding awards were presented to researchers at the University of California campuses at Irvine and San Diego; Massachusetts General Hospital; State University of New York at Buffalo; University Hospital, Leuven, Belgium; University College, Cork, Ireland; and a team from the Institut de Biologie Physico-Chimique, Paris; and the University Medical Center, Mainz, Germany.

Cystinosis is a metabolic disease that slowly destroys every organ in the body, including the liver, kidneys, eyes, muscles, thyroid and brain. There is a medicine that prolongs the children’s lives, but there is no cure. Most cystinosis sufferers succumb to the disease or its complications by age 40.

In patients with cystinosis, the amino acid cystine accumulates in the tissue due to the inability of the body to transport cystine out of the cell. This causes development of crystals, resulting in early cell death.

“The advancements achieved thus far are the result of CRF’s focused efforts and targeted approaches to research. We are dedicated to bringing the first stem cell and gene therapy clinical trial for cystinosis to reality. We hope that, if all goes well, there will be a clinical trial for a cure within the next two to three years,” she said. The CRF currently is funding 48 research studies, including 13 research fellows worldwide.

Nancy Stack and her husband, Geoffrey, a managing director of the SARES•REGIS Group, an Irvine real estate company, have a daughter, Natalie, 19, with cystinosis.

Every dollar raised by the CRF is committed for medical research. Administrative costs are privately underwritten. All grants are awarded based on evaluations by the CRF’s Scientific Review Board, which is comprised of leading doctors and research scientists in the field.

SPRING 2010 RESEARCH GRANTS FUNDED

Total: $988,759

Alan Davidson, PhD, Principal Investigator
Massachusetts General Hospital, Boston, Massachusetts
“Characterization and Rescue of CTNS-iPS Cells”
$129,557 – 1 year grant

Bruno Gasnier, PhD, Principal Investigator
Institut de Biologie Physico-Chimique, Paris, France
Ellen Closs, PhD, Co-Investigator
University Medical Center, Mainz, Germany
“Molecular Study of Lysosomal Transporters Involved in the Cystine-depleting Effect of Cysteamine”
$169,384 – 2 year grant

Patrick Harrison, PhD, Mentor and Ciaran Lee, Research Fellow
University College, Cork, Ireland
“Cystinosis Gene Repair”
$146,258 – 2 year grant

Elena Levtchenko, MD, PhD, Mentor and Joost Schoeber, PhD, Research Fellow
University Hospital, Leuven, Belgium
“Studying Podocyte Function in Nephropathic Cystinosis”
$150,000 – 2 year grant

Miriam Britt Sach, MD, PhD, Principal Investigator
University of California, San Diego
“In Vivo ATP Metabolism in Cystinosis Patients as Assessed by MR Spectroscopy”
$109,493 – 1 year grant

Jennifer Simpson, MD, Principal Investigator
James Jester, PhD, Co-Investigator
University of California, Irvine
“Novel Treatment Modalities for Corneal Cystinosis”
$180,000 – 2 year grant

Mary Taub, PhD, Principal Investigator
State University of New York at Buffalo
“Mechanisms Underlying the Fanconi Syndrome in Cystinosis”
$104,067 – 1 year grant

The Cystinosis Research Foundation is the largest non-profit provider of funds for cystinosis research in the world. For more information, call Zoe Solsby at (949) 223-7610 or visit www.cystinosisresearch.org.

LOS ANGELES, CA–(Marketwire – July 6, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mymedicalrecords.com) today announced that Jeff Holtmeier, MMR’s representative to China, will be in Zhengzhou, China next week for meetings with the Company’s China JV partner Unis-TongHe (“Unis-TH”), Hewlett-Packard China and other strategic partners regarding the planned launch of Zhengzhou City’s Electronic Medical Record (“EMR”) project. These will consist of plans to include a customized version of MMR’s proprietary Personal Health Record (“PHR”) services and professional document imaging solutions led by MMRPro, (www.mmrpro.com) and the MMRPro/Kodak Scan Station Solution. MMRGlobal has a 10-Year Joint Venture Agreement with Unis-TH in China.

“Our Joint Venture operations with Unis-TH in China are in addition to our contract with Chartis International, which has plans to begin offering MyMedicalRecords and MyEsafeDepositBox to Chartis policyholders worldwide including China,” said Robert H. Lorsch, MMRGlobal Chairman and Chief Executive Officer.

Representatives of the Unis-TongHe MMR Medical Information Technology Service Group Joint Venture (“JV”) will be formalizing plans to commence the Zhengzhou City medical records project, which includes MMR’s Personal Health Records services and other related products (www.mmrtheatre.com). Initial programs call for the provision of a variety of EMR services to China. The initial project will include deployment to one-third of Zhengzhou’s population of nearly seven (7) million and, ultimately, the JV could deploy services to the majority of Zhengzhou’s 1410 municipal health institutions. These institutions include 164 hospitals, 43 community health centers, 134 community health stations, 14 women and children health maintenance centers, 17 disease prevention and control centers and seven health supervision stations.

The first phase of the project includes two administrative regions of Zhengzhou City with more than 2.3 million residents. During the phase one trial period, the solution is expected to cover 42,231 healthcare professionals that include 16,389 assistant doctors and 16,432 registered nurses.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mmrtheatre.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. MMRGlobal, Inc. disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on the reasonable expectations of MMRGlobal, Inc. as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to the Unis-TongHe/MMR JV, both the Company’s and the JV’s business prospects, results of operations or financial condition, national and international government regulations and the risks associated with doing business across borders and territories, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

UTICA, NY–(Marketwire – July 6, 2010) –  CONMED Corporation (NASDAQ: CNMD) announced today that it expects to report second quarter 2010 financial results before the market opens on Thursday, July 29, 2010, and will also hold a conference call live over the Internet at 10:00 a.m. Eastern Time that same day. This webcast can be accessed from CONMED’s web site at www.conmed.com. Replays of the call will be made available through August 6, 2010.

The Company anticipates that forward-looking information and additional material details related to second quarter 2010 earnings and the Company’s expectations on a prospective basis may be discussed during the call. Such forward-looking information may involve risks and uncertainties such as those described in the Company’s SEC filings.

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use our medical devices. Headquartered in Utica, New York, the Company’s 3,400 employees distribute its products worldwide from several manufacturing locations.

SCOTTSDALE, AZ–(Marketwire – July 6, 2010) –  Today the recreational athlete has access to quality sports care and rehabilitation. With a foundation of chiropractic, the prevention and maintenance of sports related injuries is moving to higher levels. Practitioners offer a variety of techniques to assist the individual as a complete physical system, rather than trying to fix an isolated condition.

Dr. Wendy Weisflog, D.C., C.C.S.P., chosen as a “Top Doctor of 2009” by Phoenix Magazine, operates the Arizona Sports & Rehabilitation Center in Scottsdale, Arizona. She takes an advanced approach by introducing a variety of treatment options. “We don’t stop with the traditional chiropractic approach,” claims Dr. Weisflog. “We work with the complete individual, providing the right combination of treatments and focused lifestyle guidance. We help our patients not only deal with nagging physical problems, but set them up for long-term success.”

Chiropractic deals with the structure of the body, with an emphasis on the spine. Manipulation or “adjustment” of the spine and skeletal structure is used to realign and relieve nerve interference or other malfunction. Spinal and joint alignment is the essential building block of resolving chronic injury.

Chiropractic is accepted as a viable approach, especially in sports medicine. In a 2002 study, 31% of NFL teams use chiropractors in an official capacity as part of their staffs, with trainer referrals to chiropractors approaching 77%.

Following chiropractic treatment, a prescribed course of activity allows the body to return to normal movement without causing further damage. Various forms of massage relax muscles and soft-tissue, allowing skeletal adjustments to be sustained. Length of treatment depends on severity of the injury and the patient’s condition. At the appropriate time, exercise and strength training may be introduced to help the individual return to normal activity.

At Arizona Sports & Rehabilitation Center, the patient is encouraged to make lifestyle changes to avoid continuing aggravation. The recreational athlete benefits from the professionals that treat them, because the pros demand the best. Dr. Weisflog states, “We use a variety of programs depending on the attitude, commitment and needs of our clients. Some find acupuncture helpful, while others respond to E-Stim therapy, which involves mild electrical stimulation. Also, we give them a maintenance program which usually involves stretching and age-appropriate exercise, so they won’t need a long-term rehabilitation period.” 

Today’s amateur athlete has a wide range of top level options, all geared to getting back in the game, quickly and easily. For more information: www.azsportsrehab.com

Click here to see all recent news from this company

BURLINGTON, VT–(Marketwire – June 30, 2010) –  Marathon Health today announced that Averitt Express, a leading provider of freight transportation and supply chain management, will offer onsite health services to its associates at its corporate campus in Cookeville, TN. 

The Averitt clinic is scheduled to open in early October 2010.

Marathon Health will implement and manage the onsite health clinic for Averitt associates, spouses, and dependents over the age of six. Available services include acute and primary care, wellness and health promotion, health coaching, disease management, medication dispensing, and the Marathon eHealth Portal technology to support the delivery of care and coaching.

The opening of an onsite health clinic is a logical next step for Averitt’s health benefit strategy according to Averitt consultant Jeff Lynch, Summit Financial Group. “Over the past five years, we have systematically introduced wellness/prevention into the medical plan design, workplace policies, and employment policies. Balancing the cost pressures related to healthcare with a sincere desire to provide high-quality health benefits is a challenge for Averitt. The answer is providing Averitt associates with access to a full range of health services at work; this is a win-win for Averitt and its associates.”

“Our associates’ overall health is very important to us, and we strive to provide the appropriate tools to help them achieve the best health possible,” said Scott Wolf, Averitt vice president, corporate services. “We are very excited about how the onsite clinic will contribute to the overall health and wellbeing of our team.”

The foundation for Marathon Health services is health risk identification and mitigation. This total population health risk management approach addresses the health needs of the entire population, helping the healthy maintain good health, and helping those with costly and debilitating chronic disease to manage conditions.

“We are proud to partner with Averitt and to contribute to their vision of health and wellbeing for Averitt associates and their families,” said Jeff Shea, Marathon Health vice president.

About Averitt Express

Established in 1971, Averitt Express is a leading provider of freight transportation and supply chain management with international reach to more than 100 countries. The company specializes in delivering customized solutions with a single source of accountability for service offerings that include cross border/domestic offshore, dedicated, expedited, intermodal, international ocean/air, local customization, less-than-truckload, PortSide™, transportation management, truckload (dry van, flatbed, refrigerated, brokerage), warehousing and value-added services, including a centralized call center, strict performance metrics and an ongoing focus on green/sustainability efforts. Averitt’s technology offerings include a full suite of web-based shipping tools, electronic data interchange (EDI) and transportation and operations management systems. For more information, please call 1-800-AVERITT (283-7488) or visit http://www.averittexpress.com.

About Marathon Health

Marathon Health of Colchester, VT, offers a proven solution for helping employers reduce the total cost of healthcare. The Marathon Health approach integrates the best practices of onsite primary care, health assessment with risk identification, coaching and advocacy, and disease management for high cost chronic conditions. Marathon Health supports its unique model with an eHealth Portal delivering medical content, interactive diet and fitness tools, a personal health record, and an electronic medical record to manage care. For more information, please visit www.marathon-health.com.

NEW YORK, NY–(Marketwire – June 30, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical and biotechnology analytics company, announced that in addition to its recent investment in a medical manufacturing company, it has invested in the repurchase of 90 million shares of its common stock in a private transaction, thereby reducing the actual issued and outstanding shares to 305,857,509. Of this total, the approximately 39 million shares which are not closely held are traded in the public market. These shares constitute the public float.

Both the investment in an ongoing acquisition and the investment in the repurchase of shares will have the immediate effect of increasing shareholder equity through significantly enhanced earnings per share.

About Healthnostics

Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.

For further information please visit Healthnostics www.healthnostics.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

WINNIPEG, MANITOBA–(Marketwire – June 30, 2010) – DiaMedica Inc. (TSX VENTURE:DMA) (“DiaMedica” or the “Company”), is pleased to announce the completion today of its $2.26 million short form prospectus offering of units (the “Offering”) and its previously announced acquisition (the “Acquisition”) of Sanomune Inc., a privately held biopharmaceutical company focused on neurological disorders (“Sanomune”). 

The Offering

Pursuant to the completion of the Offering, DiaMedica has issued a total of 5,650,000 units (each a “Unit“) at a price of $0.40 per Unit for aggregate gross proceeds of $2.26 million. Each Unit is comprised of one common share in the capital of the Company (each a “Common Share“) and one Common Share purchase warrant (each a “Warrant“), with each Warrant entitling the holder thereof to acquire a further Common Share until the second anniversary of the closing of the Offering. The expiry date of the Warrants is subject to acceleration if the volume-weighted average trading price of the Common Shares on the TSX Venture Exchange (the “TSX-V“) exceeds $0.75 per share for a period of 10 consecutive trading days. 

The Offering was led by Bolder Investment Partners, Ltd., as agent (“Bolder”). In connection with the completion of the Offering, Bolder exercised its agent’s option to increase the size of the Offering by 13%, or 650,000 Units. 

The net proceeds of the Offering will be used to fund DiaMedica’s ongoing research and development programs, including planned pre-clinical trials for our lead products, and for general working capital purposes. 

As compensation for its services as agent, Bolder received a cash commission of $226,000, and received broker warrants to acquire up to 565,000 Common Shares exercisable at the price of $0.40 per share at any time on or prior to June 30, 2011.

The Acquisition

Pursuant to the completion of the Sanomune Acquisition, DiaMedica has issued a total of 12,807,377 Common Shares to Sanomune shareholders as consideration for all of the issued and outstanding shares of Sanomune.

“With the completion of this financing and the strategic acquisition of Sanomune, we have brought together two of Canada’s Top 10™ Life Sciences Companies,” stated Mr. Rick Pauls, President and Chief Executive Officer of DiaMedica. “This acquisition allows us to take advantage of a unique opportunity to strengthen our patent portfolio and expand into neurological and autoimmune disorders targeted by our lead program, DM-99/199, which has demonstrated neural protection (protects brain cells) and neural cell proliferation (creates brain cells)”.

As a result of the Acquisition, in addition to Sanomune’s lead compound, SAN-61, DiaMedica also acquires a panel of monoclonal antibodies that trigger the inhibition of glycogen synthase kinase 3 beta (GSK-3ß). GSK-3ß plays an important role as a regulatory switch for numerous cell-signaling pathways and has been linked to diabetes, cancer, infectious diseases and a variety of neurological disorders. It is anticipated that the monoclonal antibody program will compliment DiaMedica’s DM-99/199 program, which has also been shown to have GSK-3ß inhibiting properties.

As announced in its April 20, 2010 press release, DiaMedica obtained the required minority shareholder approval (the “Minority Approval”) for the Acquisition under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”), by securing written consents to the transaction from shareholders representing approximately 65% of the Common Shares held by parties eligible to vote for approval of the transaction under Part 8 of MI 61-101. This is in excess of the simple majority requirement (i.e., 50%+1) set out in MI 61-101 for such Minority Approval. 

In addition to the related parties described in DiaMedica’s February 18, 2010 press release regarding the Acquisition (each a “Related Party” and collectively, the “Related Parties”), Common Shares held by two investment funds, Manitoba Science & Technology Fund (“MST”) and Crocus Investment Fund (“CIF”) were also excluded for the purposes of obtaining Minority Approval for the Acquisition. MST and CIF each hold approximately 24.75% of the voting common shares of Genesys Ventures Inc., a Related Party, and are therefore each “a related party of an interested party” as described in MI 61-101. Immediately prior to the completion of the Acquisition and the Offering, the Related Parties, in the aggregate, beneficially owned, or exercised control or direction over, a total of 5,493,523 Common Shares, or 28.60% of the total issued and outstanding Common Shares. To the knowledge of the Company, based on public filings by each of MST and CIF, immediately prior to the completion of the Acquisition and the Offering, MST and CIF held, in the aggregate, a total of 3,065,764 Common Shares, or 15.96% of the total issued and outstanding Common Shares.

Management Changes

DiaMedica further announces the appointment of Mr. Pauls to the full-time position of President and Chief Executive Officer and the appointment of Dr. Mark Williams to Vice-President, Research. Dr. Stephen Waters has resigned from his interim role as Executive Vice-President and Interim Chief Scientific Officer.

Mr. Pauls, who has been an active board member since 2005, and is currently the Chairman of the Board of DiaMedica, has served as the acting President and Chief Executive Officer of the Company since July 2009. Mr. Pauls was previously the Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund which he was involved with from inception. While with CentreStone, Mr. Pauls led investments in Orasi Medical Inc., winner of the Red Herring Global 100; LED Medical Inc., winner of Red Herring Canada 50 award in the Health category; as well as DiaMedica and Sanomune, both named among Canada’s Top 10™ Life Sciences Companies. Prior to his role with CentreStone, Mr. Pauls was employed by Centara Corporation, another early stage venture capital fund.

“We would like to express our gratitude to Dr. Stephen Waters for his valuable contributions to our strategic planning efforts and we look forward to working with him as a consultant,” continued Mr. Pauls. “The Board of Directors of DiaMedica joins me in thanking Dr. Waters for his efforts, and we wish him continued success in his future endeavors”.

In conjunction with these management changes, the Board of Directors has approved a grant of 457,500 stock options to certain directors, executives and employees under the terms of the Company’s stock option plan. The options have an exercise price of $0.42 per share and are exercisable for a period of 5 years. This grant of such options is subject to acceptance by the TSX-V.

Please visit DiaMedica’s new company website at www.diamedica.com.

About DiaMedica and Sanomune

DiaMedica is a biopharmaceutical company, focused on developing novel treatments for diabetes and neurological disorders. The Company’s diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products have demonstrated human efficacy in lowering blood sugar levels in diabetics based on this novel nerve signaling mechanism.

As a result of the Sanomune Acquisition, DiaMedica plans to expand its DM-199 program into neurological and autoimmune disorders. Sanomune has demonstrated that its lead compound, SAN-61, a naturally occurring protein, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica has also acquired from Sanomune a panel of monoclonal antibodies targeting diabetes, neurological disorders and cancers through the inhibition of GSK-3ß.

Both DiaMedica and Sanomune were recognized as one of Canada’s Top 10™ Life Sciences Companies in 2008/2009. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations.
These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

MADISON, WI–(Marketwire – June 30, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of highly integrated radiation therapy solutions, announced today that Peking Union Medical College Hospital has selected the TomoTherapy^® treatment system to advance its cancer care capabilities. Located in Beijing, the teaching hospital is one of the most prestigious healthcare facilities in China and a leader in radiation oncology that treats more than 200 patients per day. Peking Union will become the first Ministry of Health system-based general hospital in Beijing to offer TomoTherapy technology.

“After comparing a number of radiation therapy options, we chose a TomoTherapy treatment system in order to provide the most integrated, advanced treatment platform in the world,” said Dr. Fuquan Zhang, chairman of Radiation Oncology at Peking Union Medical College Hospital. “We expect that TomoTherapy will provide advantages compared to traditional delivery methodologies, and that the simple operational platform will help increase throughput for many complex cases, while helping reduce the chance for mistakes. In other words, TomoTherapy is an efficient and advanced system that meets our demanding clinical environment.”

The TomoTherapy treatment system will be used to treat the hospital’s most challenging cases, starting with head, neck and gynecological cancers. The system’s unique helical IMRT capability enables clinicians to deliver highly conformal dose distributions to complex tumors. Additionally, the integrated CT image guidance offered by the TomoTherapy platform allows for precise patient positioning based on internal anatomy at time of treatment. This feature helps increase treatment delivery accuracy and ensure that radiation exposure to surrounding organs and tissue is minimized.

“Peking Union Medical College Hospital has a strong reputation throughout China for its radiation oncology services. With the addition of the TomoTherapy platform, clinicians there can advance their treatment capabilities with IG-IMRT, allowing them to better address more complex cases,” said Paul Baumgart, general manager of TomoTherapy’s Asia-Pacific Operations. “The introduction of TomoTherapy technology at Peking Union will provide a great showcase of the platform’s capabilities for the Chinese market, and is evidence of the growing demand for our solution in Asia.”

The TomoTherapy treatment system was sold to Peking Union Medical College Hospital by the company’s Chinese distributor TomoKnife. The system is expected to be installed later this year.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “expect,” “expected,” “should” or “will” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TomoMobile, TomoHD, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

CALGARY, AB–(Marketwire – June 30, 2010) –  Celebrities are accustomed to getting the latest and greatest products from Gifting Services. Sometimes it is a clever gadget or a miracle skin cream. Sometimes they are amused, impressed or even shocked. On occasion they are left in awe of an innovative product that is becomes an instant “must have.” This season’s newest must have item is the Advanced Whitening Toothbrush from World White Smiles. When celebs think of tooth whitening they imagine the bright LED lights from the dentist’s office. World White Smiles took those lights and put them into a toothbrush! This is the James Bond of toothbrush technology. “How did they do this?” asked Nicole Scherzinger. Celebs had a consistently similar response to Debi Mazar who said, “This is genius.” A few of the other celebs who received the products were Jodi Sweetin, AnnaLynne McCord, Patti Labelle, Snooki and Chris Bauer.

Perfect white teeth are the soul of your smile. This patented LED Light Toothbrush is a revolutionary dental care system that not only cleans the teeth but also prevents many forms of gum disease.

Features/Benefits

• Reduces bleeding gums
• Leaves teeth feeling smoother longer
• Scientifically proven to kill the photosensitive bacteria of the mouth and gums — the bacteria that causes gingivitis and other more severe forms of periodontal disease, and even kills thrush on contact
• Whitens naturally — Does not utilize harsh chemicals to whiten teeth
• Enhances the whitening capabilities of any whitening toothpaste
• Increases saliva production — Which protects teeth and gums from periodontal disease by keeping the mouth more alkaline
• Prevents halitosis

Some bacteria are photosensitive and when activated by visible light, induce a photodynamic reaction that kills them within seconds.

Deeply cleaning
Photodynamic energy can activate active oxygen ion in toothpaste and rapidly spread to teeth surrounding and every inch of space and edge where the common tooth brush is hard to reach. Clean and whiten each tooth completely. The innovative manual toothbrush is similar in outward appearance to conventional toothbrushes but that’s where the similarity ends. No toothbrush currently on the market can stand up to the superior performance of the LED Light Toothbrush. Electric toothbrushes can only brush the plaque off the tooth surface and nothing more. You can benefit from using this innovative technology today by brushing with this revolutionary toothbrush.

Natural design
Round-head brush is grinded by adopting advanced technology to nurse your teeth and gums. The handle designed by using Ergonomics can be held comfortably and controlled freely.

Battery
One AAA battery. It can be used for three months if teeth are brushed twice each day and for three minutes each time. It is safe and reliable. Photodynamic energy belongs to low energy light that is safe for gums or oral.

Affordable
We offer free Teeth Whitening Toothpaste while supplies last, you pay only a small shipping and handling fee as needed. Dentists recommend changing your toothbrush every 3-6 months.

BETHESDA, MD and FORT WAYNE, IN–(Marketwire – June 30, 2010) –  GetWellNetwork, Inc. today announced a successful collaboration with EXTENSION, INC. to enable patients at Norton Brownsboro Hospital in Louisville, Ky. to send messages directly to their attending nurse as well as to automate new patient care workflows that enable the hospital to provide better service and care more efficiently. Norton Brownsboro is one of five hospitals in the Norton Healthcare system, the Louisville area’s leading health provider.

The integration to EXTENSION® keeps the GetWellNetwork system connected to the right nurse and staff member, enabling nursing workflows that keep nurses informed and connected to their patients at all times — via the Cisco wireless device. The integration is accomplished through a new systems interface developed by GetWellNetwork using the HL7 protocol. 

EXTENSION specializes in solutions that turn Cisco Unified Communications into a clinical workflow tool by automating notifications using text messages, phone calls, and emails. It also allows nurses to acknowledge the notification directly from his/her phone and escalate the issue when needed. Through this integration effort, the GetWellNetwork system now sends alerts that inform nurses when patients have not completed important education videos or other service requests.

“The GetWellNetwork system provides us with valuable input from our patients but we needed an automated way for that information to be delivered to the handheld Cisco phones that are assigned to each of our staff on a given day,” said Doug Winkelhake, President, Norton Brownsboro Hospital. “We appreciate how quickly GetWellNetwork and EXTENSION came together to help us make patient experience and quality of care much better and more efficient.”

“By working with EXTENSION, we’re able to send actionable patient information right to the attending nurse and staff at Norton Brownsboro Hospital,” said Robin Cavanaugh, CTO, GetWellNetwork, Inc. “This integration effort is also noteworthy because it is standards-based, which means that we can implement this for any of our client hospitals who want to take the next level of patient engagement.”

“This solution was created in a way that leverages the existing process for how nurses and other staff members receive and react to other types of alerts sent by EXTENSION,” said Josh Mahler, COO, EXTENSION, INC. “By incorporating these new alerts into the existing process, minimal training was required.”

About EXTENSION, INC.
EXTENSION, INC. is based in Fort Wayne, IN and is the developer of the EXTENSION® Solution Suite (ESS). EXTENSION tightly integrates any HL7-based or web services-based medical application with Cisco Advanced Unified Communications, using standards-based protocols. EXTENSION recently earned the ‘Cisco Collaboration Partner of the Year for the US/Canada’ award at the 2010 Cisco Partner Summit. For more on EXTENSION visit www.OpenTheRedBox.com.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

SANTA ANA, CA–(Marketwire – June 30, 2010) –  SixLog Corporation, an Astro Pak company providing on-site biological decontamination and sterilization services, today announced it will be demonstrating its revolutionary iHP™ (ionized Hydrogen Peroxide) room disinfection/sterilization technology at the annual conference for APIC (Association for Professionals in Infection Control), July 12-14 at booth #2235 at the New Orleans Convention Center in New Orleans, Louisiana.

SixLog’s featured system uses iHP™ technology, the next-generation of hydrogen peroxide fogging systems. It is faster, more effective, and safer than alternatives. Originally developed for the US Department of Defense to combat biological warfare, this breakthrough technology is now available for commercial use. iHP™ has proven efficacy in a multitude of industries including Life Sciences and Pharmaceutical, and SixLog now offers its service to the healthcare industry to address the ongoing challenges resulting from a nationwide goal of preventing healthcare-associated infections (HAIs).

“I am very excited to be able to offer our room disinfection/sterilization service to the healthcare industry,” says Vanessa Valdez, general manager of SixLog. “iHP™ is a proven sterilant that not only kills all microorganisms, but their spores as well, eradicating any possible reproduction of pathogenic organisms leading to nosocomial infections. We offer fully integrated, customized solutions to meet infection prevention needs at an affordable price. iHP™ can easily augment any hospital’s terminal cleaning protocol to provide a more robust result.”

SixLog’s room disinfection/sterilization service utilizing iHP™ technology solves critical infection control challenges in the healthcare industry and is particularly effective against common “super bugs” such as MRSA, C. difficile, VRE and multi-drug resistant (MDR) Acinetobacter. iHP™ does not damage sensitive electronics and dissolves into just water and oxygen making it safe for staff, patients and visitors as well as the environment. A few examples of iHP™ room disinfection/sterilization applications include:

• Emergency and patient rooms
• Intensive care units
• Surgical suites
• Tissue culture labs
• Bone marrow transplant suites
• Blood banks
• Sputum induction areas

For more information about SixLog’s iHP™ technology or to view it in action, please visit SixLog at booth #2235 at APIC 2010 July 12-14 at the New Orleans Convention Center, or contact us at [email protected] or 877-4SIXLOG (474-9564).

About SixLog Corporation

SixLog provides on-site biological decontamination for equipment, rooms, entire buildings, and modes of transportation such as ambulances, trains, and cruise ships. Its proprietary iHP™ (ionized Hydrogen Peroxide) decontamination technology is utilized across a variety of industries including Life Sciences, Pharmaceutical, Healthcare, First Responders, Transportation, and Public Facilities. SixLog is privately held with headquarters in Santa Ana, CA. For more information, please visit www.sixlogcorp.com.

Click here to see all recent news from this company

SPRINGFIELD, OH–(Marketwire – June 30, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, has priced a public offering of 1,714,286 shares of its common stock at $3.50 per share. AdCare expects to receive net proceeds of approximately $5.5 million from the sale of the common stock. AdCare has granted a 30-day option to the underwriter to purchase up to an additional 15% or 257,143 shares to cover over-allotments. The offering is subject to customary closing conditions and is expected to close on Friday, July 2, 2010.

AdCare plans to use the net proceeds of the offering for acquisition purposes, working capital and general corporate purposes. C.K. Cooper & Company is acting as the sole manager for the public offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on May 4, 2010, which became effective on June 23, 2010. The offering will be made by a prospectus supplement and accompanying base prospectus, copies of which have been filed with the SEC.

Copies of the prospectus supplement and accompanying base prospectus may be obtained from the SEC’s website at www.sec.gov or from C.K. Cooper & Company, 18300 Von Karman Avenue, Suite 700, Irvine, California 92612, Attention: Hue Lapham/Syndicate Department, or [email protected], or via fax +1-949-477-9211.

This press release does not constitute an offer to sell or solicitation of an offer to buy any securities. Any such offer may be made only pursuant to the company’s prospectus supplement and accompanying base prospectus for the offering and only in states in which the offering is registered or exempt from registration and by broker-dealers authorized to do so. The securities offered by the prospectus involve a high degree of risk.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management, and involve known and unknown risks, results, performance or achievements of the company which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the company with the Securities and Exchange Commission and include the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

LOS ANGELES, CA–(Marketwire – June 30, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) today gave guidance in the form of projected sales, portions of which may be recognized as deferred revenue (“Sales”). For the 12 months ending December 31, 2010 the Company expects Sales of $2.7 million or 350 percent over 2009. Based on the knowledge of management today, the Company also projects Sales of $28 million for the 12 months ending December 31, 2011 or an increase of over 800 percent. Sales for the first six months of 2010 are expected to exceed the first six months of 2009 by more than 20 percent not including any revenues from International Licensing in 2010. This demonstrates that the Company’s core Sales are growing at a pace of over 100 percent after excluding the licensing revenues the Company reported last year. These projections do not include revenues from Chartis in 2010 which may occur, or any revenues from new affinity sales, China, India, integration to wireless devices, clinical trials, biotech assets or revenue that may be recognized through acquisitions.

According to Ingrid Safranek, Chief Financial Officer, “With the launch of MMRPro, the Company is taking the proactive step of early-adopting Accounting Standards Update (“ASU”) 2009-13, Revenue Recognition (Topic 605) Multiple-Deliverable Revenue Arrangements. This allows the Company to consistently record revenue on these sales up to and through the Company’s mandatory adoption date of January 1, 2011. Additionally, this new ASU is closer to the FASB’s proposed alignment with International Financial Reporting Standards. Adoption of this new standard results in revenue being reported earlier than under the old accounting rules.”

“Management has taken what we believe to be a cautious approach to our guidance by carefully evaluating our sales and marketing agreements, distribution channels and long lead times for time-to-market, which the Company has experienced in the past,” added Safranek.

The Company has modeled patient upgrades internally as follows: Patient upgrades will come from MMRPatientView through MMRPro sales from resellers and distributors, and National Payment Providers (“NPP”). The Company projects that the average MMRPro user will have 2.5 physicians, each with 2,000 active patient charts, or 5,000 patients per MMRPro placement. The Company projects that doctors will upgrade an average of two patients per month to MMRPatientView (www.mmrpatientvideos.com ),which should continue to increase year-over-year as the public becomes more aware of the importance of having a personal health record (“PHR”) and the government mandates the use of PHRs in healthcare reform. Physicians receive 35 percent of all revenue from patient upgrades, which the Company believes can result in substantially more income to doctors than the $44,000 in government stimulus programs. Kodak distributors and resellers and NPP receive an additional 15 percent as long as their MMRPro sale is active which should be no less than three years.

According to Robert H. Lorsch, Chairman and Chief Executive Officer of MMRGlobal, “In addition to the Company’s core business, we foresee incremental growth from the effects of an acquisition strategy by adding business units that sell complementary products and services to MMRPro customers, and from our targeted expansion into the Pacific Rim with Kodak, and India with Nihilent. As part of the acquisition strategy, the Company could introduce a full-blown Electronic Medical Records product after meaningful use criteria are finalized. We continue to work with GRSworldwide on opportunities to introduce the Company’s products and services to the clinical trials market. Also, it is impossible to predict revenues, if any, which could come from the Company’s pre-merger Favrille biotech assets. While the Company continues to explore opportunities involving those assets, we remain focused on our core business, which is the development and marketing of professional and consumer-based health information technology products and services.”

Last Sunday, on June 27^th, the Company ran a 30-second commercial during the 37th Annual Daytime Emmy Awards primetime television special. The Company converted more than 20 percent of all visitors to its website to an e-mail address and more than 5 percent to paid accounts despite a 30-day free trial. MMR will continue to exploit its commercial advertising on the Web and in direct marketing materials through its agreement with E-Mail Frequency.

The Company is in the process of translating its consumer websites into seven foreign languages in support of its Chartis agreement and believes that once completed, this could result in additional licensing and/or direct international marketing opportunities. To learn more about MMR Global, Inc. and its products, visit www.mymedicalrecords.com, www.mmrpro.com and view our product videos at www.mmrtheater.com.

About MMRGlobal, Inc.
MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions (www.myesafedepositbox.com), serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the risk the Company’s products are not adopted or viewed favorably by the healthcare community, risks related to the current uncertainty and instability in financial and lending markets, timing and volume of sales and installations, length of sales cycles and the installation process, market acceptance of new product introductions, ability to establish and maintain strategic relationships, ability to identify and integrate acquisitions, relationships with licensees, competitive product offerings and promotions, compliance with and changes in government laws and regulations and future changes and initiatives in the healthcare industry, undetected errors in our products, risks related to third party vendors, risks related to obtaining and integrating third-party licensed technology, acceptance of the Company’s marketing and promotional campaigns, risks related to a security breach by third parties, maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets, uncertainties associated with doing business internationally across borders and territories, and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. 

Click here to see all recent news from this company

SPRINGFIELD, OH–(Marketwire – June 29, 2010) –  AdCare Health Systems, Inc. (NYSE Amex: ADK), an Ohio-based long-term care, home care and management company, intends to offer shares of its common stock in an underwritten public offering. C.K. Cooper & Company is acting as the sole manager for the public offering.

AdCare plans to use the net proceeds of the offering for acquisition purposes, working capital and general corporate purposes.

AdCare previously filed a registration statement, together with the accompanying base prospectus, with the Securities and Exchange Commission (SEC) on May 4, 2010, which became effective on June 23, 2010. Investors are advised to carefully consider the investment objectives, risks and expenses of AdCare before investing. The base prospectus contains certain information about AdCare and should be read carefully before investing. A prospectus supplement describing the particular terms of the offering will be filed with the SEC and will form a part of the effective registration statement. When available, copies of the prospectus supplement and accompanying base prospectus may be obtained from the SEC’s website at www.sec.gov or from C.K. Cooper & Company, 18300 Von Karman Avenue, Suite 700, Irvine, California 92612, Attention: Hue Lapham/Syndicate Department, or [email protected], or via fax +1-949-477-9211.

This press release does not constitute an offer to sell or solicitation of an offer to buy any securities. Any such offer may be made only pursuant to the company’s prospectus for the offering and only in states in which the offering is registered or exempt from registration and by broker-dealers authorized to do so. The securities offered by the prospectus involve a high degree of risk.

About AdCare Health Systems
AdCare Health Systems, Inc. (NYSE Amex: ADK) develops, owns and manages assisted living facilities, nursing homes and retirement communities and provides home healthcare services. Prior to becoming a publicly traded company in November of 2006, AdCare operated as a private company for 18 years. AdCare’s 900 employees provide high-quality care, management services and other services for patients and residents residing in 19 facilities, seven of which are assisted living facilities, 11 skilled nursing centers and one independent senior living community. The company owns eight of those facilities. In the ever-expanding marketplace of long-term care, AdCare’s mission is to provide quality healthcare services to the elderly. For more information about AdCare, visit www.adcarehealth.com.

Safe Harbor Statement
Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available to management, and involve known and unknown risks, results, performance or achievements of the company which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by the company with the Securities and Exchange Commission and include the company’s ability to secure lines of credit and/or an acquisition credit facility, find suitable acquisition properties at favorable terms, changes in the health care industry because of political and economic influences, changes in regulations governing the industry, changes in reimbursement levels including those under the Medicare and Medicaid programs and changes in the competitive marketplace. There can be no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements.

MADISON, WI–(Marketwire – June 29, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that it has signed an equipment supply group purchasing agreement with Premier Purchasing Partners, L.P., the group purchasing unit of Premier, Inc. The agreement provides TomoTherapy greater reach into Premier’s not-for-profit hospitals and health centers, which includes 2,300 U.S. hospitals and more than 67,000 other healthcare facilities, while enabling Premier members to access special pricing and terms for innovative radiation oncology solutions and establishing a streamlined purchasing solution for them.

TomoTherapy’s radiation therapy solutions enable high treatment quality for a broad patient population, with capabilities to treat cancers throughout the body.

“We are pleased to be partnering with Premier, the leading group purchasing organization serving not-for-profit healthcare institutions,” said Fred Robertson, TomoTherapy CEO. “In addition to providing TomoTherapy expanded reach through Premier’s network, this agreement will offer Premier’s members better access to highly precise cancer treatment solutions.”

About Premier Healthcare Alliance
Premier is a performance improvement alliance of more than 2,300 U.S. hospitals and 67,000-plus other healthcare sites working together to achieve high quality, cost-effective care. Owned by not-for-profit hospitals, Premier maintains the nation’s most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier works with the Centers for Medicare & Medicaid Services and the United Kingdom’s National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has offices in San Diego, Philadelphia and Washington. http://www.premierinc.com.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

NEW YORK, NY–(Marketwire – June 29, 2010) –  Neostem (NYSE Amex: NBS) was cleared for manufacturing penicillin and cephalosporin powder for injection at its new manufacturing facility by China’s State Food and Drug Administration. The news helped convince WBB Securities to upgrade the company from ‘sell’ to ‘hold’.

WBB Securities initially extended coverage on Neostem on June 3, 2010 with a ‘sell’ recommendation, however, it should be noted that the investment banking firm began touting four other stem cell companies in late April. The fact that Neostem raised $5 million in cash through a placement in late June had no bearing on the investment banker’s outlook, however, after the Chinese State Food and Drug Administration cleared the way to begin selling drugs manufactured at Neostem’s new, state-of-the-art facility in China, WBB Securities analysts had second thoughts and upgraded the company’s shares.

Neostem announced Tuesday morning that two of its manufacturing lines were up and running at its China pharmaceutical manufacturing unit which would increase production capacity by more than 50%. With that country’s State FDA giving the green light to manufacture penicillin and cephalosporin powder for injection, sales forecasts are expected to show substantial gains.

Based on sales results for 2009 and the new manufacturing plant’s increased capacity, sales could increase by more than $20 million.

Neostem founder and CEO, Dr. Robin Smith, noted that Eyre was one step closer to becoming “one of the largest antibiotic producers in Eastern China.”

Note to Editors: “News Features” are stories provided to publishers copyright-free for print or online display at no charge. All we ask is that publishers include our byline (AXcess News) as the source, or if online, link to our Web Site: http://www.axcessnews.com. If you are interested in displaying our news on a regular basis, please contact our editorial department at: 775-461-0362 or by email at: [email protected].

Click here to see all recent news from this company

LAS VEGAS, NV–(Marketwire – June 29, 2010) –  VisualMED Clinical Solutions Corp. (The “Company”) (PINKSHEETS: VMCS) (FRANKFURT: VA6) announces that it has received in the past three weeks firm orders for its Clinical Information System from independent private medical facilities worth an aggregate amount of 2.6 million.

The deals are multi-year rental agreements that will see the deployment of the Company’s signature smart Electronic Health Record, with full CPOE, decision support and medical alerts, over the next 3 months. A significant part of the implementation support and help desk will be outsourced for greater speed and efficiency.

Starting in April the Company has been receiving increasing requests for quotes as medical facilities seek to meet the 2011 deadline for the first and largest disbursement to physicians under ARRA provisions. The key for physicians to secure these payments is meeting the meaningful use criteria which can only be demonstrated by using a true intelligent CPOE such as the ones VisualMED has been offering for many years.

“Thanks to the new reforms our time has come,” says Chairman Gerard Dab. “We are now becoming a mainstream product line that helps physicians meet new regulatory standards. Providers have only five years to implement systems that offer meaningful use before they face punitive measures, and there is a shortage of expertise in the marketplace to do so.” 

VisualMED appears to be benefiting from the new regulatory environment created by the Healthcare Information Technology provisions of the American Recovery and Reinvestment Act (ARRA), which has earmarked close to $40 Billion to promote the widespread adoption of systems that correspond to federal norms of meaningful use, such as those owned and marketed by the Company since 2006.

Medical institutions are under increasing pressure to adopt such technologies. There is an industry-wide rush to identify systems that can help physicians qualify for federal ARRA reimbursement grants. This has led to an increased demand for products and services from companies that can deliver the rich medical content and suitable interoperability required.

The Company continues to work with its network of licensees and will seek to expand its network of strategic alliances. It expects to be profitable for a second consecutive year and has continued to contain operating costs.

ABOUT VISUALMED

VisualMED markets smart EHR with Clinical Information Systems (CIS) and Computerized Physician Order Entry that meet the new regulatory environment ushered in by the American Recovery and Reinvestment Act of 2009 and the Health Reform Act of 2010.

We offer a powerful technology platform both scalable and interoperable, developed at a cost of some forty million dollars and tested over many years in tertiary care and ambulatory environments.

Our solutions help medical facilities reduce mortality and morbidity due to medical errors, increase provider efficiency and bring down operating costs. Their key clinical components are a core solution in the new agenda to promote greater patient safety and reduce risks due to medication errors.

Detailed information on our company and its products is available on our web site at www.visualmedsolutions.com

FORWARD-LOOKING STATEMENTS

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of the Company. These statements are based on suppositions and uncertainties as well as on management’s best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for the Company’s products and services, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

WEST HARTFORD, CT–(Marketwire – June 29, 2010) –  ORLive, the vision of improving health, presents a personalized partial knee replacement surgery. Presented by ConforMIS, the surgery will be broadcast live from University of Wuerzburg Orthopedic Center for Musculoskeletal Research.

This week ORLive also invites you take part in the latest installment of the Virtual Brain Tumor Board, and to watch and learn from our library of spine surgery videos.

NEW ON ORLIVE

LIVE SURGERY — German Language Broadcast to Europe, Featuring ConforMIS iUni^® G2 Patient Specific Partial Knee Replacement System
Live June 29, 2010, 11:00 AM EDT

Live from the University of Wuerzburg Orthopedic Center for Musculoskeletal Research, a live partial knee replacement surgery using the ConforMIS iUni^® G2 system. The broadcast will feature Dr. Wolfgang Fitz of Brigham and Women’s Hospital, Dr. Ulrich Nöth and Dr. Maximilian Rudert, both of the University of Wuerzburg Orthopedic Center for Musculoskeletal Research, presenting and performing the surgery. Learn more about this broadcast, presented entirely in German, at http://www.orlive.com/conformis-inc-/videos/n-chste-generation-patienten-spezifischer-knieoberfl-chenersatz-mit-conformis-iuni-sup-/sup-g2-17-00-uhr-mez-1.

Viewers will be able to interact and ask questions via the ORLive website. Learn more about this program, and request a reminder on ORLive.com.

ORLIVE REFERRALS — Week of June 28, 2010
Each week ORLive highlights on-demand videos for our membership and visitors.

Spine Health Referral: XLIF^® Procedure from Tampa General Hospital

CME Referral: Complex Cases in Cardiovascular Anesthesiology

Viewer’s Referral: Revision Knee Surgery Featuring the Zimmer^® NexGen^® LCCK System, from Zimmer

HIGHLIGHTS

NOW ON-DEMAND — Advances in Treating Pediatric Epilepsy
Now Available On-Demand

If a child’s seizures can’t be controlled with medications, surgery may be the solution. See how the Neurosurgical team at NewYork-Presbyterian Phyllis & David Komansky Center for Children’s Health is making advancements in epilepsy. Hosted by Philip Stieg, MD, PhD, and featuring Jeffrey Greenfield, MD, PhD, Samual Weinstein, MD, and Theodore Schwartz, MD, this program goes in depth into the latest surgical advancements and options for patients.

Viewers of this video are invited to interact with the surgeons via the ORLive website, and to join the community and receive regular updates from the NewYork-Presbyterian Phyllis & David Komansky Center for Children’s Health on pediatric epilepsy.

LIVE PROGRAM: Minimally Invasive Heart Surgery: Robot Assisted Mitral Valve Repair
Now Available On-Demand

Baptist Health South Florida will take center stage when viewers watch as cardiac surgeon Dr. Lynn Seto uses the da Vinci Robotic Surgical System to perform a mitral valve repair.

The webcast will be moderated by television personality Diane Magnum. She will moderate commentary by Dr. Seto and cardiologists Dr. Paul Seigel and Dr. Romeo Majano, who will explain the benefits of having valve repair surgery. Additionally, the patient who was operated on in late May will share his experience about his diagnosis and recovery. Viewers also can choose to watch the procedure in Spanish.

SUPPLEMENTAL CONTENT — VOX ORLive
This procedure is also featured in an episode of VOX ORLive, an audio podcast featuring the latest advancements in medicine, surgery, and medical technology.

About ORLive
ORLive is the leading provider of video communication channels to the healthcare community. Working collaboratively with hospitals and device manufacturers, ORLive produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations. The ORLive broadcasting network provides an intimate look at over 650 live and on-demand surgeries to a global audience, streaming over 50,000 hours of programming each month. The ORLive network can be found on-line at www.ORLive.com.

id=”nav_links”>